Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Rajat Bose of rajatkbose.com is of the view that o
Mitesh Thacker of miteshthacker.com is of the view
Ashwani Gujral of ashwanigujral.com recommends buy
Axis Direct has recommended Hold rating on Biocon
ICICI Direct recommended hold rating on Biocon wit